ArticleMediators of inflammation2026
A Novel CAF-Related Signature for Precise Prediction of Clinical Outcomes and Immunotherapy Response for Breast Cancer Patients: Based on Multiomics Analyses and Experimental Validation.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveBreast cancer (BC) remains a leading cause of cancer-related mortality worldwide. Cancer-associated fibroblasts (CAFs) is a central stromal component of the tumor microenvironment (TME), critically influence BC progression and therapeutic resistance. However, the association between CAF heterogeneity and patient prognosis or response to immunotherapy remains poorly characterized. Here, we aimed to develop a CAF-associated gene signature by integrating single-cell RNA sequencing (scRNA-seq) and bulk RNA-seq data to predict clinical outcomes and immunotherapeutic response in BC.
methodsGene expression profiles and clinical data from BC patients were sourced from TCGA and GEO databases. scRNA-seq data preprocessed (quality control, PCA, UMAP using Seurat) identified CAF-related genes. Prognostic genes were identified via univariate Cox, lasso, and multivariate Cox regression. Single-cell Gene Set Enrichment Analysis (scGSEA) assessed the signature's link to immune infiltration and immunotherapy genes. R tools evaluated signature characteristics and real-world applications. GO enrichment analysis was used to explore signaling pathways. CAF factor expression and CD8
resultsscRNA-seq analysis identified multiple CAF-specific marker genes that formed the core of our signature. Eight genes (ANXA5, APOD, CXCL14, GSN, IGFBP4, PPIB, TCF7L2, and TMEM98) were associated with favorable prognosis (low-risk), whereas three genes (SDC1, EMP1, and FAM114A1) conferred higher risk. A risk score model based on these 11 genes independently predicted overall survival (OS) across diverse BC pathological subtypes, demonstrating robust prognostic accuracy. Immune infiltration analysis revealed significantly reduced immune cell abundance in the high-risk group compared to the low-risk group, suggesting diminished responsiveness to immunotherapy. In tumor tissues relative to adjacent nontumor tissues, mRNA and protein levels of the high-risk genes (SDC1, EMP1, and FAM114A1) were consistently elevated (all p < 0.05). Moreover, both Western blotting and mIF showed significantly higher CAF abundance in high-risk samples (p < 0.01), concomitant with markedly lower CD8
conclusionWe present a novel CAF associated gene signature that robustly predicts prognosis and immunotherapy response in BC. As an independent prognostic indicator strongly correlated with immune infiltration, this model holds promise for guiding personalized therapeutic strategies. Future validation in large, multicenter cohorts and extension to other malignancies are warranted to facilitate clinical translation of CAF targeted biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.